NCT07392892 2026-04-13
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer
Phase 2/3 Recruiting
Clinical Trials
10 trialsNCT07221149 2026-04-02
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06988475 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06826079 2025-09-09
SNCCTGC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2/3 Recruiting
NCT07018661 2025-08-27
PLASTIC-3
Leiden University Medical Center
Phase 2/3 Recruiting
NCT06028737 2025-05-06
OCTASUR
Ukrainian Society of Clinical Oncology
Phase 2/3 Recruiting
NCT06782412 2025-02-07
FAPIDO
KU Leuven
Phase 2/3 Recruiting
NCT06504732 2025-01-20
To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 2/3 Recruiting
NCT06221748 2024-04-03
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
Phase 2/3 Recruiting
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting